Company Name: FibroGen, Inc.

FibroGen, Inc. is a biopharmaceutical company. The company is engaged in the development and commercialization of therapeutics utilizing fibrosis and hypoxia-inducible factor (HIF) biology.  The company’s lead product candidate is a treatment for anemia in chronic kidney disease.

Ticker Symbol: FGEN (NASDAQ)

Company Website: www.fibrogen.com

Social Media: FibroGen LinkedIn

Headquarters: San Francisco, CA